集落刺激因子1受体在胶质瘤中的研究进展  

Research Progress of Colony-stimulating Factor 1 Receptor in Glioma

作　　者：徐邦杰 朱思齐 丁涟沭[1] XU Bangjie;ZHU Siqi;DING Lianshu(Department of Neurosurgery,the Affiliated Huai′an No.1 People′s Hospital of Nanjing Medical University,Huai′an 223300,China;Department of Oncology,the Affiliated Huai′an No.1 People′s Hospital of Nanjing Medical University,Huai′an 223300,China)

机构地区：[1]南京医科大学附属淮安第一医院神经外科,江苏淮安223300 [2]南京医科大学附属淮安第一医院肿瘤科,江苏淮安223300

出　　处：《医学综述》2022年第20期4021-4026,共6页Medical Recapitulate

摘　　要：胶质瘤是中枢神经系统中最常见的原发性肿瘤,目前标准的治疗方案以手术切除为主、辅助放化疗等综合治疗,但患者预后仍不乐观。集落刺激因子1受体(CSF-1R)是调节单核巨噬细胞生存、增殖和分化的重要因子,其在胶质瘤中高表达,具有促进肿瘤增殖、侵袭等能力。目前靶向抑制CSF-1/CSF-1R信号轴在多种肿瘤免疫治疗中发挥重要作用,且与肿瘤相关巨噬细胞密切相关,但治疗效果仍存在争议,肿瘤耐药性成为临床一大难题。因此,CSF-1R联合其他治疗逐渐成为发展方向。Glioma is the most common primary tumor in the central nervous system.The current standard of treatment is surgical resection combined with adjuvant chemoradation therapy and other comprehensive treatments,but the prognosis of the patients is still poor.Colony-stimulating factor 1 receptor(CSF-1R)is an important factor regulating the survival,proliferation and differentiation of mononuclear macrophages.CSF-1R is highly expressed in glioma and promotes tumor proliferation,invasion and other abilities.At present,targeted inhibition of the CSF-1/CSF-1R signaling axis plays an important role in a variety of tumor immunotherapy,and is closely related to tumor-associated macrophages.However,the therapeutic effect is controversial and tumor drug resistance has become a major clinical problem.Therefore,CSF-1R combined with other treatments has gradually become the development direction.

关 键 词：胶质瘤 集落刺激因子1受体 集落刺激因子1受体抑制剂 肿瘤相关巨噬细胞 

分 类 号：R739.41[医药卫生—肿瘤]